testicular cancer therapeutics - pipeline assessment

1. Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

2. The Testicular Cancer Therapeutics Market is Forecast to Show Gradual Growth Until 2017 GlobalData estimates that the global testicular cancer therapeutics market was valued at $91m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 3.8% over the next seven years, to reach $118m by 2017. The gradual growth of the market is primarily attributed to the expected continued domination of generics in the testicular cancer therapeutics market, as no disease-modifying molecule is expected to launch during the forecast period to 2017. The Testicular Cancer Therapeutics Market has High Unmet Need The global testicular cancer therapeutics market is attractive, with high unmet need. The unmet need in the market is around 49%, which is approximately valued at $45m. The testicular cancer pipeline is weak, with no molecules in the late stage of clinical development. The testicular cancer therapeutics market is not expecting the launch of any molecule in the near future, suggesting that the unmet need will remainhigh during the forecast period. Scope for Entrants with Better Efficacy and Safety Profiles Testicular cancer is a market that is underserved by currently marketed drugs, mainly in terms of safety issues (serious adverse events).

3. The market therefore provides opportunity for the entrants with better efficacy and safety profiles, which have a novel mechanism of action. Weak Clinical Pipeline with Fewer Molecules GlobalData’s analysis found that the testicular cancer therapeutic pipeline is weak. The therapeutics pipeline for testicular cancer consists of only three molecules in various stages of clinical development. Two molecules are in Phase II and one is in Phase I. Currently, no molecule is in late stages of clinical development. Moreover, the participation of companies in clinical trials for testicular cancer is not significant. Future Implications for the Testicular Cancer Therapeutics Market Generic products are likely to remain as the strong players in the testicular cancer therapeutics market. This is largely due to the fact that currently no molecules are present in the late stages of clinical development for the treatment of testicular cancer. This indicates that the unmet need is likely to remain high and the market is estimated to show a gradual growth during the forecast period to 2017. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Testicular-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

4. GlobalData, the industry analysis specialist, has released its new report, “Testicular Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global testicular cancer market. The report identifies the key trends shaping and driving the global testicular cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global testicular cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Visit our report store: http://www.globaldata.com For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Testicular-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017

5. For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782